News

FDA approves risankizumab for pediatric psoriasis and psoriatic arthritis in children six years and older, expanding treatment options for...

Silo Pharma's SPC-15 PTSD treatment passes nine months of stability testing, clearing a key CMC milestone toward IND submission...

Seres presents SER-155 data for checkpoint inhibitor enterocolitis, targeting a steroid-sparing approach to oncology-related toxicity management.

ProQR's AX-0810 Phase 1 study demonstrates target engagement through an 8-fold increase in serum bile acids, validating the Axiomer...

Innovative Molecules launches Phase 2a Trial of Adibelivir for genital herpes, testing a helicase-primase inhibitor against acyclovir-resistant strains.

FDA backs Entera Bio's Phase 3 plan for oral EB613 osteoporosis drug, targeting injection-free anabolic therapy for postmenopausal women.

Phathom completes Phase 2 Vonoprazan EoE Trial ahead of schedule with 95 patients enrolled. Topline data expected by Q4...

GENFIT's GNS561 shows no dose-limiting toxicities in Phase 1b cholangiocarcinoma trial combining autophagy inhibition with MEK inhibition in KRAS-mutated...

FDA rejected cytisinicline over manufacturing issues at a third-party facility, not clinical safety, with resubmission planned for Q4 2026.

Revolution Medicines opens RASolute 305 Trial of zoldonrasib in RAS G12D pancreatic cancer, testing the G12D-selective inhibitor in the...